IHS Chemical Week

Regions :: Western Europe :: U.K.

DSM to Manufacture C. difficile Compound for U.K. Biotech Firm

12:14 AM MDT | June 11, 2010 | Deepti Ramesh

DSM BioSolutions, part of the DSM Pharma cluster, says it has entered into an agreement with biotechnology company Novacta Biosystems (Welwyn Garden City, U.K.) for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. Financial terms of the deal were not disclosed. DSM has completed the process development and has commenced cGMP-manufacturing of the Novacta compound at its microbial fermentation biotech facility at Capua, Italy.  The product will initially be used for pre-clinical and phase I...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa